相似文献
1
Treatment of schizophrenia negative symptoms: future prospects.
Schizophr Bull. 2006 Apr;32(2):234-7. doi: 10.1093/schbul/sbj055. Epub 2006 Feb 21.
2
Schizophrenia: D4 receptor elevation. What does it mean?
J Psychiatry Neurosci. 1994 May;19(3):171-6.
3
Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
Biol Psychiatry. 1996 Feb 1;39(3):227-9. doi: 10.1016/0006-3223(95)00387-8.
4
New antipsychotic agents and the future.
J Clin Psychiatry. 1985 Apr;46(4 Pt 2):51-3.
5
Dopamine receptors and schizophrenia.
Biochem Soc Trans. 1996 Feb;24(1):202-5.
6
[Pathophysiology of schizophrenia and its impact on pharmacotherapy].
Fortschr Neurol Psychiatr. 2005 Nov;73 Suppl 1:S32-7. doi: 10.1055/s-2005-915546.
7
From pharmacological profiles to clinical outcomes.
Int Clin Psychopharmacol. 2000 Dec;15 Suppl 4:S1-4.
8
Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
Acta Psychiatr Scand. 2007 Feb;115(2):93-100. doi: 10.1111/j.1600-0447.2007.00992.x.
9
Executive functioning component mechanisms and schizophrenia.
Biol Psychiatry. 2008 Jul 1;64(1):26-33. doi: 10.1016/j.biopsych.2008.04.027.
10
The dopamine D4 receptor in schizophrenia: an update.
Psychol Med. 1996 Mar;26(2):221-7. doi: 10.1017/s0033291700034619.
引用本文的文献
1
Subtyping first-episode psychosis based on longitudinal symptom trajectories using machine learning.
Npj Ment Health Res. 2025 May 15;4(1):18. doi: 10.1038/s44184-025-00129-7.
2
Somatic symptoms in schizophrenia: Association with socio-demographic and clinical characteristics, disability and quality of life.
Indian J Psychiatry. 2023 Jul;65(7):749-754. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_571_22. Epub 2023 Jul 12.
3
Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).
Front Psychiatry. 2022 Jan 24;12:770592. doi: 10.3389/fpsyt.2021.770592. eCollection 2021.
4
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review.
Ther Adv Psychopharmacol. 2022 Jan 28;12:20451253211066642. doi: 10.1177/20451253211066642. eCollection 2022.
5
Facial and Vocal Markers of Schizophrenia Measured Using Remote Smartphone Assessments: Observational Study.
JMIR Form Res. 2022 Jan 21;6(1):e26276. doi: 10.2196/26276.
6
Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review.
Neurol Int. 2021 Jul 1;13(3):279-296. doi: 10.3390/neurolint13030029.
7
Computer Vision-Based Assessment of Motor Functioning in Schizophrenia: Use of Smartphones for Remote Measurement of Schizophrenia Symptomatology.
Digit Biomark. 2021 Jan 21;5(1):29-36. doi: 10.1159/000512383. eCollection 2021 Jan-Apr.
8
Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.
Int J Neuropsychopharmacol. 2020 Dec 29;23(12):775-782. doi: 10.1093/ijnp/pyaa006.
9
Impact of Positive Emotion Regulation Training on Negative Symptoms and Social Functioning in Schizophrenia: A Field Test.
Front Psychiatry. 2019 Jul 26;10:532. doi: 10.3389/fpsyt.2019.00532. eCollection 2019.
10
Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial.
Neuropsychiatr Dis Treat. 2019 May 8;15:1141-1150. doi: 10.2147/NDT.S196086. eCollection 2019.
本文引用的文献
1
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Schizophr Res. 2004 Feb 1;66(2-3):89-96. doi: 10.1016/S0920-9964(03)00129-4.
2
Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia.
Clin Neuropharmacol. 2003 Nov-Dec;26(6):317-21. doi: 10.1097/00002826-200311000-00011.
3
Management of the negative symptoms of schizophrenia: new treatment options.
CNS Drugs. 2003;17(11):793-823. doi: 10.2165/00023210-200317110-00003.
4
Components of the smooth pursuit function in deficit and nondeficit schizophrenia.
Schizophr Res. 2003 Sep 1;63(1-2):39-48. doi: 10.1016/s0920-9964(02)00388-2.
5
Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia.
Psychiatr Clin North Am. 2003 Mar;26(1):191-211. doi: 10.1016/s0193-953x(02)00017-5.
6
Bipolar II with and without cyclothymic temperament: "dark" and "sunny" expressions of soft bipolarity.
J Affect Disord. 2003 Jan;73(1-2):49-57. doi: 10.1016/s0165-0327(02)00320-8.
7
Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.
Clin Neuropharmacol. 2002 Sep-Oct;25(5):272-5. doi: 10.1097/00002826-200209000-00010.
8
Clinical profile of an atypical antipsychotic: risperidone.
Schizophr Bull. 2002;28(1):43-61. doi: 10.1093/oxfordjournals.schbul.a006925.
9
Odor identification, eye tracking and deficit syndrome schizophrenia.
Biol Psychiatry. 2002 May 15;51(10):809-15. doi: 10.1016/s0006-3223(01)01319-1.
10
Donepezil in schizophrenia--is it helpful? An experimental design case study.
Acta Psychiatr Scand. 2001 Dec;104(6):469-72. doi: 10.1046/j.0001-690x.2001.acp1c008d.x.
Zotero 插件